CN1823784A - 厄贝沙坦氢氯噻嗪分散片 - Google Patents
厄贝沙坦氢氯噻嗪分散片 Download PDFInfo
- Publication number
- CN1823784A CN1823784A CN 200510135308 CN200510135308A CN1823784A CN 1823784 A CN1823784 A CN 1823784A CN 200510135308 CN200510135308 CN 200510135308 CN 200510135308 A CN200510135308 A CN 200510135308A CN 1823784 A CN1823784 A CN 1823784A
- Authority
- CN
- China
- Prior art keywords
- irbesartan
- hydrochlorothiazide
- cross
- carboxymethyl cellulose
- dispersible tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006185 dispersion Substances 0.000 title description 7
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims abstract description 35
- 229960002198 irbesartan Drugs 0.000 claims abstract description 35
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims abstract description 35
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims abstract description 28
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960002003 hydrochlorothiazide Drugs 0.000 claims abstract description 28
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 17
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims abstract description 17
- 239000000314 lubricant Substances 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 239000008107 starch Substances 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 3
- 239000008101 lactose Substances 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 30
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 27
- 238000004132 cross linking Methods 0.000 claims description 27
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 27
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 27
- 239000007919 dispersible tablet Substances 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 19
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 16
- 230000001476 alcoholic effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 229920000881 Modified starch Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 108010011485 Aspartame Proteins 0.000 claims description 11
- 239000000605 aspartame Substances 0.000 claims description 11
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 11
- 229960003438 aspartame Drugs 0.000 claims description 11
- 235000010357 aspartame Nutrition 0.000 claims description 11
- -1 correctives Substances 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 45
- 239000003814 drug Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 206010020772 Hypertension Diseases 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000005541 ACE inhibitor Substances 0.000 description 7
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 7
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 7
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 4
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 4
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- NZPSYYOURGWZCM-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one;6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)C(CCCC)=NC21CCCC2 NZPSYYOURGWZCM-UHFFFAOYSA-N 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000010924 used plastic bottle Substances 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000651 tasosartan Drugs 0.000 description 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
处方号 | 处方1 | 处方2 | 处方3 |
硬度 | 4.74kg | 4.94kg | 5.44kg |
脆碎度 | 0.2% | 0.1% | 0.3% |
分散均匀性 | 2分48秒 | 3分16秒 | 2分20秒 |
处方号 | 处方4 | 处方5 | 处方6 |
硬度 | 4.98kg | 5.07kg | 4.98kg |
脆碎度 | 0.2% | 0.3% | 0.1% |
分散均匀性 | 2分38秒 | 2分00秒 | 3分10秒 |
处方号 | 处方5 | 处方7 |
硬度 | 5.07kg | 5.31kg |
脆碎度 | 0.3% | 0.1% |
分散均匀性 | 2分00秒 | 1分20秒 |
项目批号 | 间隔时间(月) | 外观色泽 | 分散均匀性 | 有关物质 | 溶出度(%) | 含量(%) | |||
氢氯噻嗪(A) | 厄贝沙坦(%) | 氢氯噻嗪 | 厄贝沙坦 | 氢氯噻嗪 | 厄贝沙坦 | ||||
041216 | 01236 | 白色片白色片白色片白色片白色片 | 符合规定符合规定符合规定符合规定符合规定 | 0.0370.0410.0390.0440.054 | 0.330.310.340.390.36 | 100.399.398.896.199.0 | 91.289.888.889.888.9 | 100.0100.299.899.499.5 | 99.1100.499.899.298.3 |
041218 | 01236 | 白色片白色片白色片白色片白色片 | 符合规定符合规定符合规定符合规定符合规定 | 0.0380.0420.0410.0430.052 | 0.330.300.340.320.36 | 99.799.198.895.698.1 | 90.891.488.889.788.3 | 100.4100.599.7100.099.4 | 99.5100.299.5100.098.0 |
041220 | 01236 | 白色片白色片白色片白色片白色片 | 符合规定符合规定符合规定符合规定符合规定 | 0.0380.0430.0400.0430.053 | 0.340.320.350.300.38 | 99.199.398.996.598.9 | 90.090.788.990.789.4 | 100.5100.299.299.698.9 | 99.0100.199.599.699.1 |
项目批号 | 间隔时间(月) | 性状 | 分散均匀性 | 有关物质 | 溶出度(%) | 含量(%) | |||
氢氯噻嗪(A) | 厄贝沙坦(%) | 氢氯噻嗪 | 厄贝沙坦 | 氢氯噻嗪 | 厄贝沙坦 | ||||
041216 | 036 | 白色片白色片白色片 | 符合规定符合规定符合规定 | 0.0370.0410.046 | 0.330.250.32 | 100.396.898.5 | 91.291.588.7 | 100.0100.2100.1 | 99.1100.099.2 |
041218 | 036 | 白色片白色片白色片 | 符合规定符合规定符合规定 | 0.0380.0400.044 | 0.330.280.34 | 99.799.5100.8 | 90.893.791.1 | 100.499.5100.2 | 99.599.698.9 |
041220 | 036 | 白色片白色片白色片 | 符合规定符合规定符合规定 | 0.0380.0410.045 | 0.340.280.33 | 99.197.9100.1 | 90.092.990.7 | 100.5100.5100.11 | 99.0100.498.6 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101353088A CN100417384C (zh) | 2005-12-28 | 2005-12-28 | 厄贝沙坦氢氯噻嗪分散片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101353088A CN100417384C (zh) | 2005-12-28 | 2005-12-28 | 厄贝沙坦氢氯噻嗪分散片 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1823784A true CN1823784A (zh) | 2006-08-30 |
CN100417384C CN100417384C (zh) | 2008-09-10 |
Family
ID=36934726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101353088A Expired - Fee Related CN100417384C (zh) | 2005-12-28 | 2005-12-28 | 厄贝沙坦氢氯噻嗪分散片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100417384C (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1199641C (zh) * | 2002-10-24 | 2005-05-04 | 王登之 | 一种用于治疗高血压的复方厄贝沙坦胶囊 |
CN1714794A (zh) * | 2004-06-28 | 2006-01-04 | 刘凤鸣 | 厄贝沙坦氢氯噻嗪分散片及其制备方法 |
CN1732953B (zh) * | 2005-09-02 | 2010-05-05 | 姚俊华 | 一种治疗高血压的分散片 |
-
2005
- 2005-12-28 CN CNB2005101353088A patent/CN100417384C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN100417384C (zh) | 2008-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1036763C (zh) | 制备药物片剂和药物颗粒的方法 | |
CN1215833C (zh) | 快速崩解的甲基纤维素片剂 | |
CN1296387C (zh) | 纤维素粉末 | |
CN1089471A (zh) | 稳定的延长释放口服组合物 | |
CN1168094A (zh) | 可直接压制的高负荷扑热息痛制剂 | |
CN1216869C (zh) | 赛利可喜的多态晶型 | |
CN1762357A (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
CN1094756C (zh) | 解热镇痛组合药剂 | |
CN1527700A (zh) | 制备苯妥英钠剂型的压缩方法 | |
CN1523981A (zh) | 具有高api含量的药物片剂 | |
CN1684681A (zh) | 比西发定制剂 | |
CN100339072C (zh) | 一种美索巴莫干混悬剂 | |
CN1768744A (zh) | 制备复方法莫替丁咀嚼片的方法 | |
CN1823784A (zh) | 厄贝沙坦氢氯噻嗪分散片 | |
CN1264520C (zh) | 一种阿奇霉素肠溶制剂及其制备方法 | |
CN1352558A (zh) | 即释型口服用药物组合物 | |
CN1397556A (zh) | 地洛他定多元酸碱金属或碱土金属盐复合盐及其药用组合物 | |
CN1887277A (zh) | 含有降血脂成分的分散片及其制备方法 | |
CN1843343A (zh) | 美索巴莫分散片 | |
CN1301108C (zh) | 美他多辛分散片及其制备方法 | |
CN1298316C (zh) | 含有ltb4拮抗剂的药物制剂 | |
CN100340239C (zh) | 穿心莲内酯分散片 | |
CN100336511C (zh) | 口服罗红霉素控释制剂 | |
CN1923182A (zh) | 拉西地平口腔崩解片制剂及其制备方法 | |
CN1063039A (zh) | 爱尔芒克雷特的固态剂型及其制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TIANJIN KANGCHEN RUIXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YAN JIE |
|
CP03 | Change of name, title or address |
Address after: 300203, friendship road, Tianjin, Hexi District B building, seven Co-patentee after: Tianjin Huairen Pharmaceutical Co.,Ltd. Patentee after: Tianjin Kangchen Ruixin Pharmaceutical Group Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee before: Yan Jie |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080910 Termination date: 20181228 |
|
CF01 | Termination of patent right due to non-payment of annual fee |